Related Experiment Video
Updated: Oct 15, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
Collaborating with AIProSaB-A researcher's perspective on patient advocacy for progeria
Giovanna Lattanzi1, Lavinia Arseni2
1Istituto di Genetica Molecolare "Luigi Luca Cavalli-Sforza" - Sede di Bologna c/o Istituto Ortopedico Rizzoli, Italy.
Abstract:
Progeria is an extremely rare genetic disease in which affected individuals age rapidly due to a specific mutation in the LMNA gene, which results in the production of progerin, an abnormal protein that damages cell nuclei and causes progressive multi-organ disease. AIProSaB is an Italian association founded by Sammy Basso, who was diagnosed with progeria at the age of two, and by his parents. The association supports research, promotes experimental therapies, and provides information for families and clinicians, with a strong emphasis on understanding LMNA/progerin biology and developing targeted treatments and gene-editing approaches. As part of our series on patient advocacy, FEBS Letters interviews Dr. Giovanna Lattanzi, a researcher at the CNR Institute of Molecular Genetics 'Luigi Luca Cavalli-Sforza' in Bologna on the aims, achievements, and activities of AIProSaB.
More Related Videos
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Patient-centered Care
EPS and iPS Cells in Disease Research
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Kidney Disease III: Interprofessional Care
Peripheral Artery Disease I: Introduction

